Monoclonal antibodies targeting EGFR/HER2 and clinical outcomes in cancer treatment

2013 ◽  
pp. 2-8
Author(s):  
Jan B Vermorken
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
Clinical Outcomes

Abstract 46: Clinical Outcomes and Quality Metrics of Cervical Cancer Treatment in Rwanda

2021 ◽  
Author(s):  
Victoria Umutoni ◽  
Cyprien Shyirambere ◽  
Ethan Katznelson ◽  
Cam Nguyen ◽  
Jean Bosco Bigirimana ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Treatment ◽  
Clinical Outcomes ◽  
Quality Metrics

Monoclonal Antibodies in Cancer Treatment

BioDrugs ◽  
1999 ◽  
Vol 12 (3) ◽  
pp. 209-236 ◽  
Author(s):  
Katherine Alpaugh ◽  
Margaret von Mehren
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 737-737 ◽  
Author(s):  
Benoist Chibaudel ◽  
Thierry Andre ◽  
Benoit Samson ◽  
Marie-Line Garcia-Larnicol ◽  
Jérôme Dauba ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Maintenance Therapy ◽  
Metastatic Colorectal Cancer ◽  
Clinical Outcomes ◽  
Primary Tumor ◽  
Phase Iii ◽  
Primary Tumors ◽  
Phase Iii Trial ◽  
Mutational Status

737 Background: Primary tumor sidedness (PTS) could be a predictive maker for treatment efficacy of EGFR inhibitors monoclonal antibodies in patients with wild-type (WT) RAS metastatic colorectal cancer (MCRC), cetuximab having limited efficacy in patients with WT-RAS right-sided tumors. DREAM study demonstrated that adding erlotinib, an oral EGFR tyrosine kinase inhibitor (TKI) to bevacizumab during maintenance therapy improved clinical outcomes (RR, PFS, OS) in patients with MCRC, whatever KRAS status. The aim of this post-hoc analysis is to evaluate the clinical outcomes according to KRAS mutational status and PTS when adding erlotinib to bevacizumab maintenance therapy. Methods: PTS was retrospectively collected in patients from the DREAM phase III trial treated with bevacizumab with or without erlotinib as maintenance therapy for MCRC who have been controlled by induction therapy. The limit for the definition of PTS was splenic flexure, and rectal tumors were considered as left-sided tumors. The primary endpoint was overall survival (OS). Results: Among 452 patients who received maintenance therapy, PTS ascertainment was 84.7% (n = 383) with 265 (71.0%) patients having left-sided primary tumor and 108 (28.9%) having right-sided primary tumors (3 patients had both and tumor location was unknown in 7 patients). Median OS and treatment effect are presented in table 1. Conclusions: The greatest OS benefit of adding erlotinib to bevacizumab maintenance therapy was observed in patients with WT-KRAS and right-sided MCRC, suggesting a clinical impact of the different mechanism of action between EGFR TKI and monoclonal antibodies. Clinical trial information: NCT00265824. [Table: see text]

Immunization Effect of Monoclonal Antibodies against Tumor-Associated Antigens during Cancer Treatment

1993 ◽  
Vol 690 (1 Specific Immu) ◽  
pp. 337-339
Author(s):  
JAN FAGERBERG ◽  
JAN-ERIK FRÖDIN ◽  
PETER RAGNHAMMAR ◽  
MICHAEL STEINITZ ◽  
HANS WIGZELL ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
Tumor Associated Antigens

3-Tesla MRI-Based Adaptive Brachytherapy for Cervix Cancer: Treatment Technique and Initial Clinical Outcomes

Brachytherapy ◽  
2013 ◽  
Vol 12 ◽  
pp. S52
Author(s):  
Jordan Kharofa ◽  
Natalya Morrow ◽  
Tracy Kelly ◽  
Jason Rownd ◽  
Eric Paulson ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Clinical Outcomes ◽  
Cervix Cancer ◽  
3 Tesla ◽  
Treatment Technique ◽  
3 Tesla Mri

scholarly journals Monoclonal Antibodies for Cancer Treatment

2021 ◽  
Author(s):  
Annemeri Livinalli ◽  
Taís Freire Galvão
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Treatment ◽  
Tumor Cells ◽  
Standard Of Care ◽  
Mechanisms Of Action ◽  
Clinical Applications ◽  
Human Cancers ◽  
Therapeutic Monoclonal Antibodies

Therapeutic monoclonal antibodies have emerged in the 1990 decade as an important option for cancer treatment. These molecules have a diverse set of clinically relevant antitumor mechanisms, directly targeting tumor cells. It has been established as “standard of care” for several human cancers. This chapter reviews the use of monoclonal antibodies in oncology and introduces available biosimilars. The requirements for biosimilar antibody development, mechanisms of action and current clinical applications for cancer treatment is also presented.

Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases

Immunotherapy ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 241-254 ◽  
Author(s):  
Rossella Talotta ◽  
Francesco Rucci ◽  
Gianfranco Canti ◽  
Francesco Scaglione
Keyword(s):  
Monoclonal Antibodies ◽  
Autoimmune Diseases ◽  
Cancer Treatment ◽  
Pros And Cons
Sign in / Sign up

Export Citation Format

Share Document